1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed chronic lymphocytic leukemia
    Meeting Abstract

    Pagel, J. M.; Coutre, S. E.; Furman, R. R.; Sharman, J. P.; Cheson, B. D.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2015)

    Fulltext@MSK | Save
  • The number of CD163-positive cells in the microenvironment and peripheral blood lymphocyte-to-monocyte-ratio (LMR) is associated with poor outcome in patients with diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Matsuki, E.; Bohn, O. L.; Pichardo, J.; Zelenetz, A.; Younes, A.; Teruya-Feldstein, J.
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Distrust and conflict in sickle cell disease: Intersecting narratives of patients and physicians
    Meeting Abstract

    Tsyvkin, E.; Riessman, C.; Mathew, P.
    Blood (2015)

    Fulltext@MSK | Save
  • Phase 1 study of CB-839, a first-in-class, glutaminase inhibitor in patients with multiple myeloma and lymphoma
    Meeting Abstract

    Vogl, D. T.; Younes, A.; Stewart, K.; Orford, K. W.; Bennett, M.; Siegel, D.; Berdeja, J. G.
    Blood (2015)

    Fulltext@MSK | Save
  • Refractory T-cell prolymphocytic leukemia with JAK3 mutation: In vitro and clinical synergy of tofacitinib and ruxolitinib
    Meeting Abstract

    Wei, M.; Koshy, N.; van Besien, K.; Inghirami, G.; Horwitz, S. M.
    Blood (2015)

    Fulltext@MSK | Save
  • Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era
    Meeting Abstract

    Vardhana, S. A.; Moskowitz, C. H.; Sauter, C. S.; Matasar, M. J.; Galasso, N.; Woo, K. M.; Zhang, Z. G.
    Blood (2015)

    Fulltext@MSK | Save
  • Veliparib (ABT-888), bendamustine, and rituximab (VBR) is well tolerated and efficacious in patients with lymphoma: Final analysis of a phase 1b clinical trial of VB and a cohort expansion of VBR in patients with B-cell lymphoma
    Meeting Abstract

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Younes, A.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Safety and clinical activity of atezolizumab (anti-PDL1) in combination with obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphoma
    Meeting Abstract

    Till, B. G.; Park, S. I.; Popplewell, L. L.; Goy, A.; Penuel, E.; Venstrom, J. M.; Liu, B.; Fingerle-Rowson, G.; Byon, J.; Woodard, P.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Long-term follow up of pediatric patients with Hodgkin lymphoma treated with high dose therapy and autologous stem cell transplantation
    Meeting Abstract

    Roth, L. G.; O'Donohue, T.; Trippett, T.; Klein, E.; Kernan, N. A.; Kobos, R.; Prockop, S.; Scaradavou, A.; Shukla, N.; Steinherz, P. G.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • A detailed evaluation of transplant-related toxicities and outcome for patients with CNS lymphoma (CNSL) consolidated with high-dose therapy and autologous stem cell transplantation (HDT-ASCT) using thiotepa, busulfan (Bu), cyclophosphamide (TBC) conditioning
    Meeting Abstract

    Scordo, M.; Bhatt, V.; Hsu, M.; Omuro, A. M.; Matasar, M. J.; DeAngelis, L.; Dahi, P. B.; Moskowitz, C. H.; Giralt, S. A.; Sauter, C. S.
    Blood (2015)

    Fulltext@MSK | Save